TNF and colitis: In particular, EP-1 has shown the ability to increase the activity of superoxide dismutase enzymes in an in vivo experimental colitis model, thereby reducing malondialdehyde and proinflammatory markers (i.e., TNF-α, IL-1, and IL-6) (9).